Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Pfizer Inc (PFE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Pfizer Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Pfizer Inc trades at $24.21 (market cap $137.19B). The key difference: Pfizer Inc is far larger — about 30.6× ACADIA Pharmaceuticals Inc.'s market cap, and Pfizer Inc pays a 7.15% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PFE | |
|---|---|---|
Market Cap | $4.49B | $137.19B |
Sector | Health | Health |
52-Week High | $28.06 | $28.56 |
52-Week Low | $20.06 | $23.29 |
Enterprise Value | $3.69B | $187.84B |
Volume | — | 29,869,932 |
Dividend Yield | — | 7.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Pfizer (PFE) trades at $23.72, down 2.47% on the day, with a bearish technical signal from moving averages but recent earnings beats. The stock has a P/E of 18.11 and net income margin of 11.83%, supported by strong cash flow from operations of $11.70B in 2025. Recent news highlights pipeline progress in obesity and oncology, with dividends of $0.43 paid semi-annually.
The outlook is mixed: analyst consensus is a 'Hold' with a $27.63 price target, implying potential upside, but risks include patent cliffs and competitive pressures. Revenue has declined from pandemic peaks, yet cost controls sustain profitability. Investors may find value if pipeline catalysts materialize, though near-term volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
